NCT05080790 2025-08-17
DiTuSarc
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
Clinical Trials
37 trialsNCT03336983 2024-08-01
BonEnza
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT00525759 2023-11-24
ANZAC
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 2 Completed
NCT03358017 2023-10-19
YAPPETIZER
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT01951586 2021-10-25
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Amgen
Phase 2 Completed
NCT00295867 2020-05-12
Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
University of California, San Francisco
Phase 2 Completed
NCT00305695 2020-03-24
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
GOG Foundation
Phase 2 Completed
NCT00213980 2019-11-27
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT00582556 2019-11-26
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
University of Wisconsin, Madison
Phase 2 Completed
NCT01367288 2019-05-28
NEOZOL
Hospices Civils de Lyon
Phase 2 Completed
NCT01194440 2018-09-12
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00399802 2018-08-16
A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01204203 2017-05-24
UAB0901
University of Alabama at Birmingham
Phase 2 Completed
NCT01472146 2017-05-09
ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Instituto Nacional de Cancer, Brazil
Phase 2 Completed
NCT02784652 2017-03-29
Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors
Severance Hospital
Phase 2 Completed
NCT00577642 2017-03-10
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
Massachusetts General Hospital
Phase 2 Completed
NCT00321932 2017-03-09
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
University of Minnesota
Phase 2 Completed
NCT00247650 2017-03-01
Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy
Novartis
Phase 2 Completed
NCT00081159 2016-11-10
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00903162 2016-04-18
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00083382 2015-06-24
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
University of Arkansas
Phase 2 Completed
NCT00151073 2015-01-22
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00972959 2014-08-05
Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
University of Athens
Phase 2 Completed
NCT00242203 2013-08-13
Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00554918 2013-08-07
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00181584 2013-07-11
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00039104 2013-06-05
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00558272 2013-05-27
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
AstraZeneca
Phase 2 Completed
NCT00490698 2013-03-18
Zoledronate With Atorvastatin in Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00301873 2013-02-18
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
Duke University
Phase 2 Completed
NCT00697619 2012-03-07
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
Sun Yat-sen University
Phase 2 Completed
NCT00760370 2011-12-07
Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer
Vejle Hospital
Phase 2 Completed
NCT00263484 2011-07-21
dtZ
Gleneagles Hospital
Phase 2 Completed
NCT01341262 2011-04-25
THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase 2 Completed
NCT00181558 2010-05-10
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
Massachusetts General Hospital
Phase 2 Completed
NCT00636740 2009-02-20
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
Merrion Pharmaceuticals, LLC
Phase 2 Completed
NCT00072930 2008-01-15
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
MedImmune LLC
Phase 2 Completed